Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
REVIEW
Precision Medicine in Idiopathic Pulmonary Fibrosis The dawn of wishful thinking
| 1 | Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece |
| 2 | Second Respiratory Medicine Department, “Attikon” University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece |
| 3 | First Academic Department of Pneumonology, Hospital for Diseases of the Chest, “Sotiria”, Medical School, University of Athens, Athens, Greece |
CORRESPONDING AUTHOR
Argyris Tzouvelekis
Biomedical Sciences Research Center “Alexander Fleming”, Division of Immunology, Vari 16672, Athens, Greece
Biomedical Sciences Research Center “Alexander Fleming”, Division of Immunology, Vari 16672, Athens, Greece
Pneumon 2016;29(3):217–223
KEYWORDS
precision medicine personalized medicine idiopathic pulmonary fibrosis fibromics prognosis treatment response
ABSTRACT
The conceptualization of precision medicine and the determinants of individuality in disease predisposition and treatment response represent a methodological revival of an emblematic figure of ancient Greece, called Hippocrates. The Human Genome Project truly revolutionized the quest for genomic anatomy and set the basis for molecular profiling of each individual in the context of the disease. Almost a year ago USA president Obama announced a research initiative that aims to revolutionize a new era in precision medicine mainly focusing in the area of oncology (www.whitehouse.gov/precisionmedicine). Despite all these cornerstone events precision medicine approaches in chronic lung diseases and particularly IPF have significantly lagged behind. For many chronic lung diseases we apply theoretically live-saving treatments without absolute-knowledge of their pathogenesis and without taking into consideration disease complexity and heterogeneity. As a consequence many of these therapeutic approaches lead to fatal side-effects. This short review article aims to summarize the current state of knowledge in the prognostic and therapeutic field of IPF, underline mistakes that have been applied in the field of clinical trials and have been carried out for many years and assess ways to optimize the use of “omics” in the everyday clinical practice in order to reformulate the Hippocrates commandment “to help, or do no harm".
REFERENCES (60)
1.
Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS one 2007;2:e482.
2.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011;183:788-824.
3.
Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine 2012;156:684-91.
4.
Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. American Journal of Respiratory and Critical Care Medicine 2003;167:962-9.
5.
Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7.
6.
Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013;143:1699-708.
7.
Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8.
8.
Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow’s ear. Thorax 2013;68:309-10.
9.
Savale L, Jais X, Montani D, Sitbon O, Simonneau G, Humbert M. Treatment of pulmonary arterial hypertension in 2011: what’s new since the 2009 ERS/ESC guidelines? Presse Medicale 2011;40(Suppl 1):1S54-60.
10.
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. New Engl J Med 1999;341:1264-9.
11.
Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
12.
King TE, Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8.
13.
Bouros D, Antoniou KM, Tzouvelekis A, Siafakas NM. Interferongamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy 2006;6:1051-60.
14.
King TE, Jr., Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;177:75-81.
15.
King TE, Jr., Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2011;184:92-9.
16.
Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2012;186:88-95.
17.
Tzouvelekis A, Margaritopoulos G, Loukides S, Bouros D. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? American Journal of Respiratory and Critical Care Medicine 2013;187:213-4.
18.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
19.
King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
20.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
21.
Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory Research 2016;17:14.
22.
Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
23.
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid 2015;10:89-98.
24.
Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. The Journal of Pharmacology and Experimental Therapeutics 1999;291:367-73.
25.
Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. The Journal of Pharmacology and Experimental Therapeutics 1999;289:211-8.
26.
Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE, Jr., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
27.
Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. The Lancet Respiratory Medicine 2014;2:17-9.
29.
Spagnolo P, Sverzellati N, Rossi G, et al. Idiopathic pulmonary fibrosis: an update. Annals of Medicine 2015;47:15-27.
30.
Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management 2015;11:359-70.
31.
Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine 2015;21:470-8.
32.
Wei R, Li C, Zhang M, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. Translational research: the Journal of Laboratory and Clinical Medicine 2014;163:494-502.
33.
Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. American Journal of Respiratory and Critical Care Medicine 2014;189:214-22.
34.
Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157-79.
35.
Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
36.
Wang C, Zhuang Y, Guo W, et al. Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. PloS one 2014;9:e104919.
37.
Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192-200.
38.
Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-9.
39.
Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-26.
40.
Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proceedings of the National Academy of Sciences of the United States of America 2007;104:7552-7.
41.
Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;178:729-37.
42.
Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. The Lancet Respiratory Medicine 2013;1:309-17.
43.
Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2015;192:1475-82.
44.
Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. The European Respiratory Journal 2014.
45.
Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 2015;34:538-46.
46.
Yang IV, Pedersen BS, Rabinovich E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2014;190:1263-72.
47.
Milosevic J, Pandit K, Magister M, et al. Profibrotic role of miR154 in pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 2012;47:879-87.
48.
Huleihel L, Ben-Yehudah A, Milosevic J, et al. Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. American Journal of Physiology Lung Cellular and Molecular Physiology 2014;306:L534-42.
49.
Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2010;182:220-9.
50.
Montgomery RL, Yu G, Latimer PA, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO molecular medicine 2014;6:1347-56.
51.
Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. The Journal of Clinical Investigation 2014;124:1622-35.
52.
Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycininduced pulmonary fibrosis in mice. Molecular therapy: The Journal of the American Society of Gene Therapy 2012;20:1251- 60.
53.
Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 2011;45:287-94.
54.
Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. The Journal of Experimental Medicine 2010;207:1589-97.
55.
Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire 2015;93:159-70.
56.
Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Translational research: The Journal of Laboratory and Clinical Medicine 2011;157:191-9.
57.
Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Science Translational Medicine 2013;5:205ra136.
58.
Tzouvelekis A, Herazo-Maya J, Sakamoto K, Bouros D. Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis. Current Topics in Medicinal Chemistry 2016;16:1587- 98.
59.
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016;375:717-29.
60.
Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. European Respiratory Review: an official journal of the European Respiratory Society 2013;22:148-52.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.